OGEN Oragenics Inc.

0.97
+0.18  (+23%)
Previous Close 0.79
Open 0.8
52 Week Low 0.35
52 Week High 1.12
Market Cap $53,701,919
Shares 55,362,803
Float 53,492,201
Enterprise Value $37,405,797
Volume 37,413,872
Av. Daily Volume 4,605,841
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
AG013
Oral mucositis (OM)
Phase 2
Phase 2
Phase 2 data released April 15, 2020 did not meet primary endpoint.

Latest News

  1. Corporate presentation and live webcast scheduled for June 10, 2020 at 2:10 pm ET

    Oragenics, Inc. (NYSE:OGEN), announced today that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc., will give a virtual corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9th to 12th, 2020.

    The presentation will be held on Wednesday, June 10, 2020 at 2:10 pm ET, followed by a live Q&A session with registered investors and other conference attendees. A live webcast of the presentation will be available here https://www.webcaster4.com/Webcast/Page/2038/35043. Dr.. Joslyn will be available for one-on-one meetings online as well. Interested investors may request a meeting time by emailing:

    Corporate presentation and live webcast scheduled for June 10, 2020 at 2:10 pm ET

    Oragenics, Inc. (NYSE:OGEN), announced today that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc., will give a virtual corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9th to 12th, 2020.

    The presentation will be held on Wednesday, June 10, 2020 at 2:10 pm ET, followed by a live Q&A session with registered investors and other conference attendees. A live webcast of the presentation will be available here https://www.webcaster4.com/Webcast/Page/2038/35043. Dr.. Joslyn will be available for one-on-one meetings online as well. Interested investors may request a meeting time by emailing: .

    About Oragenics, Inc.

    Oragenics, Inc. is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease and oral mucositis. Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from the novel coronavirus, SARS-CoV-2, which causes COVID-19. The TerraCoV2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health, which issued a worldwide, nonexclusive intellectual property license to Noachis Terra. In addition, Oragenics also has two exclusive worldwide channel collaborations, one with Precigen, Inc.'s subsidiaries relating to the treatment of oral mucositis and the other with ILH Holdings, Inc., relating to the development of novel antibiotics.

    For more information about Oragenics, please visit www.oragenics.com.

    Safe Harbor Statement

    Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's current views with respect to future events and performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

    View Full Article Hide Full Article
  2. NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9th-12th, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.

    Company

    Ticker

    Webcasting Link

    ACCO Brands Corporation

    ACCO

    Participating in meetings only

    Alimera Sciences, Inc.

    ALIM

    https://www.webcaster4.com/Webcast/Page/2038/35019

    Annovis Bio

    ANVS

    https://www.webcaster4.com/Webcast/Page/2038/35035

    AquaBounty Technologies, Inc.

    AQB

    https://www.webcaster4.com/Webcast/Page/2038/35133

    Arch Therapeutics, Inc.

    ARTH

    https://www.webcaster4.com/Webcast/Page/2038/35130

    Artelo Biosciences…

    NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9th-12th, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.

    Company

    Ticker

    Webcasting Link

    ACCO Brands Corporation

    ACCO

    Participating in meetings only

    Alimera Sciences, Inc.

    ALIM

    https://www.webcaster4.com/Webcast/Page/2038/35019

    Annovis Bio

    ANVS

    https://www.webcaster4.com/Webcast/Page/2038/35035

    AquaBounty Technologies, Inc.

    AQB

    https://www.webcaster4.com/Webcast/Page/2038/35133

    Arch Therapeutics, Inc.

    ARTH

    https://www.webcaster4.com/Webcast/Page/2038/35130

    Artelo Biosciences, Inc.

    ARTL

    https://www.webcaster4.com/Webcast/Page/2038/35016

    Avalon Adv Materials

    AVLNF

    https://www.webcaster4.com/Webcast/Page/2038/35132

    Bellicum Pharmaceuticals

    BLCM

    https://www.webcaster4.com/Webcast/Page/2038/35045

    C-Bond Systems

    CBNT

    https://www.webcaster4.com/Webcast/Page/2038/35029

    Endra Life Sciences

    NDRA

    https://www.webcaster4.com/Webcast/Page/2038/35129

    Energy Focus, Inc.

    EFOI

    https://www.webcaster4.com/Webcast/Page/2038/35027

    Equillium

    EQ

    https://www.webcaster4.com/Webcast/Page/2038/35188

    Exro Technologies Inc.

    EXROF

    https://www.webcaster4.com/Webcast/Page/2038/35052

    GreenPower Motor Company

    GPV

    https://www.webcaster4.com/Webcast/Page/2038/35185

    Hecla Mining Company

    HL

    Participating in meetings only

    Heidrick & Struggles International, Inc.

    HSII

    https://www.webcaster4.com/Webcast/Page/2038/35053

    Helius Medical Technologies

    HSDT

    https://www.webcaster4.com/Webcast/Page/2038/35021

    Heritage Global Inc

    HGBL

    https://www.webcaster4.com/Webcast/Page/2038/35131

    Ideal Power

    IPWR

    https://www.webcaster4.com/Webcast/Page/2038/35031

    IMAC Holdings, Inc.

    IMAC

    https://www.webcaster4.com/Webcast/Page/2038/35146

    Lincoln Educational Services

    LINC

    https://www.webcaster4.com/Webcast/Page/2038/35028

    MailUp Group

    MAIL

    https://www.webcaster4.com/Webcast/Page/2038/35047

    Marrone Bio

    MBII

    https://www.webcaster4.com/Webcast/Page/2038/35033

    Medexus

    MDP.V

    https://www.webcaster4.com/Webcast/Page/2038/35128

    Medicenna Therapeutics

    TSX: MDNA

    https://www.webcaster4.com/Webcast/Page/2038/35034

    Milestone Scientific

    MLSS

    https://www.webcaster4.com/Webcast/Page/2038/35125

    My Size, Inc.

    MYSZ

    https://www.webcaster4.com/Webcast/Page/2038/35024

    Nephros

    NEPH

    https://www.webcaster4.com/Webcast/Page/2038/35014

    NewAge Beverage

    NBEV

    https://www.webcaster4.com/Webcast/Page/2038/35141

    Nova Leap Health Corp

    NLH

    https://www.webcaster4.com/Webcast/Page/2038/35042

    Oblong Inc.

    OBLG

    https://www.webcaster4.com/Webcast/Page/2038/35025

    OncoSec Medical Incorporated

    ONCS

    https://www.webcaster4.com/Webcast/Page/2038/35011

    Oragenics

    OGEN

    https://www.webcaster4.com/Webcast/Page/2038/35043

    PDS Biotechnology Corporation

    PDSB

    https://www.webcaster4.com/Webcast/Page/2038/35018

    Safeguard Scientifics, Inc.

    SFE

    https://www.webcaster4.com/Webcast/Page/2038/35143

    SELLAS Life Sciences Group, Inc.

    SLS

    Participating in meetings only

    ShiftPixy

    PIXY

    https://www.webcaster4.com/Webcast/Page/2038/35032

    Sigma Labs, Inc.

    SGLB

    https://www.webcaster4.com/Webcast/Page/2038/35153

    Sono-Tek Corporation

    SOTK

    https://www.webcaster4.com/Webcast/Page/2038/35022

    Timber

    Private

    https://www.webcaster4.com/Webcast/Page/2038/35017

    Tinybeans Group Limited

    TNY.AX

    https://www.webcaster4.com/Webcast/Page/2038/35046

    Tonix Pharmaceuticals Holding Corp.

    TNXP

    https://www.webcaster4.com/Webcast/Page/2038/35044

    TransGlobe Energy

    TGA

    https://www.webcaster4.com/Webcast/Page/2038/35051

    Trxade Group, Inc.

    MEDS

    https://www.webcaster4.com/Webcast/Page/2038/35123

    Ur-Energy Inc.

    URG

    https://www.webcaster4.com/Webcast/Page/2038/35030

    VIQ Solutions, Inc.

    VQS.V

    https://www.webcaster4.com/Webcast/Page/2038/35145

    Western Magnesium

    MLYF

    https://www.webcaster4.com/Webcast/Page/2038/35050

    About the Investor Summit

    The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Having produced successful conferences over the past 5 years, the upcoming event will be the 2nd virtual edition added to our growing portfolio where hundreds of high-quality meetings between executives and investors will take place over 4 days. We pride ourselves on building community and providing a platform for our industry and look forward to launching new features at the upcoming Summer Summit such as virtual roundtable discussions and a stock pitch session to promote networking in a virtual format.

    To register for the upcoming Investor Summit, visit our website at www.investorsummitgroup.com

    Media Partner: Investor Brand Network, www.InvestorBrandNetwork.com

    News Compliments of ACCESSWIRE

    FOR MORE INFORMATION

    Please visit: www.investorsummitgroup.com
    Or, contact Cassandra Miller at

    SOURCE: The Investor Summit Group

    View source version on accesswire.com:
    https://www.accesswire.com/592484/47-Public-Companies-to-present-at-the-Summer-Virtual-Investor-Summit-on-June-9th-12th

    View Full Article Hide Full Article
  3. Oragenics, Inc. (NYSE:OGEN), (the "Company" or "Oragenics"), today announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company's SARS CoV-2 vaccine candidate. Under the terms of the agreement, Aragen will provide cell line development services to Oragenics to aid in the development of Oragenics' TerraCoV2, which could provide specific immunity from the novel coronavirus ("SARS-CoV-2"), the root cause of coronavirus disease 2019 ("COVID-19").

    "Developing a variety of vaccine alternatives is critical to bringing the SARS-Cov-2 pandemic under…

    Oragenics, Inc. (NYSE:OGEN), (the "Company" or "Oragenics"), today announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company's SARS CoV-2 vaccine candidate. Under the terms of the agreement, Aragen will provide cell line development services to Oragenics to aid in the development of Oragenics' TerraCoV2, which could provide specific immunity from the novel coronavirus ("SARS-CoV-2"), the root cause of coronavirus disease 2019 ("COVID-19").

    "Developing a variety of vaccine alternatives is critical to bringing the SARS-Cov-2 pandemic under control. Utilizing the technology created at NIH with Aragen's pre-clinical development capabilities will help us accelerate the development of the TerraCov2 vaccine candidate. We believe the relationship between the companies will result in advancement of the vaccine candidate into the clinic as rapidly as possible," said Alan Joslyn, Ph.D., President and CEO of Oragenics.

    "We're delighted to initiate this project with Oragenics. Our hope is that the combined efforts of Oragenics and Aragen can accelerate TerraCoV2 development and provide a vital response to COVID-19 and the devastating pandemic it has caused," said Axel Schleyer, CEO of Aragen.

    About Oragenics, Inc.

    Oragenics, Inc. is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease and oral mucositis. Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from the novel coronavirus, SARS-CoV-2, which causes COVID-19. The TerraCoV2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health, which issued a worldwide, nonexclusive intellectual property license to Noachis Terra. In addition, Oragenics also has two exclusive worldwide channel collaborations, one with Precigen, Inc.'s subsidiaries relating to the treatment of oral mucositis and the other with ILH Holdings, Inc., relating to the development of novel antibiotics.

    For more information about Oragenics, please visit www.oragenics.com.

    About Aragen Bioscience, Inc.

    Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of in vitro and in vivo services for the discovery, production, characterization, activity and efficacy assessment and development of biologic and diagnostic products. www.aragenbio.com

    View Full Article Hide Full Article
  4. Addition of Industry Veteran Bolsters Oragenics' Focus on Vaccine Development

    Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), today announced that it has increased the size of its board of directors and appointed Ms. Kim Murphy to the board, effective May 1, 2020. As an experienced vaccine marketing and commercialization professional, Ms. Murphy's appointment coincides with the Company's strategic shift to the development of a vaccine candidate for the novel coronavirus (SARS-CoV-2), which causes the coronavirus disease 2019 ("COVID-19").

    Dr. Frederick Telling, the Company's Chairman said, "As Oragenics makes its fundamental transition into vaccine development, I knew that our board needed someone capable of rising to the challenge…

    Addition of Industry Veteran Bolsters Oragenics' Focus on Vaccine Development

    Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), today announced that it has increased the size of its board of directors and appointed Ms. Kim Murphy to the board, effective May 1, 2020. As an experienced vaccine marketing and commercialization professional, Ms. Murphy's appointment coincides with the Company's strategic shift to the development of a vaccine candidate for the novel coronavirus (SARS-CoV-2), which causes the coronavirus disease 2019 ("COVID-19").

    Dr. Frederick Telling, the Company's Chairman said, "As Oragenics makes its fundamental transition into vaccine development, I knew that our board needed someone capable of rising to the challenge presented by the COVID-19 pandemic. Of the possible candidates, Kim's extensive knowledge of vaccine development and her experience in vaccine commercialization represented what Oragenics needed as our business evolves. Kim is highly-qualified to guide Oragenics in its new goal of creating a vaccine candidate that can wipe out the harm caused by COVID-19, and we look forward to drawing on her vaccine industry background." Dr. Telling continued, "On behalf of the entire board of directors and our management team, I am delighted to welcome Kim to Oragenics as a member of the board."

    "I am humbled by the invitation to join Oragenics' board of directors as it refocuses its business on developing a vaccine candidate to treat COVID-19. While I believe the challenges that the Company—and the world—face ahead are great, I believe now is an excellent time to share my vaccine marketing and commercialization experience with Oragenics' forward-thinking management team and dynamic board. I am eager to represent Oragenics on this new journey and I look forward to representing and collaborating with the Company's shareholders, management team, and the other members of the board," said Ms. Murphy.

    Ms. Murphy brings a wealth of vaccine industry knowledge and experience that are highly-relevant to the Company's strategic acquisition of Noachis Terra, as well as the development of the Company's other product candidates. Ms. Murphy is an accomplished leader and medical-industry professional with substantial experience in the vaccine development arena, having previously served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc ("GSK"). While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Ms. Murphy also managed a 2,000-employee vaccine development, sales, manufacturing, and distribution team and was responsible for the integration planning of GSK's acquisition of Novartis AG's vaccine division. Earlier in her career, she also worked in commercialization and marketing roles within Novartis Vaccines and Diagnostics Inc. and Merck & Co., Inc. Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, biotechnology industry groups, and academic and philanthropic societies. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph's University.

    Following the addition of Ms. Murphy, the Company's board will be composed of six members. Ms. Murphy will be expected to stand for election with the Company's other directors in connection with the Company's 2020 annual meeting of the shareholders.

    About Oragenics, Inc.

    Oragenics, Inc. is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for oral mucositis and novel antibiotics against infectious disease. Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the Company is dedicated to the commercialization and development of a vaccine candidate providing limited immunity from the novel coronavirus, SARS-CoV-2, which causes the coronavirus disease 2019, COVID-19. The TerraCoV2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health, which is under a worldwide, nonexclusive intellectual property license to Noachis Terra. In addition, Oragenics also has two exclusive worldwide channel collaborations, one with Precigen, Inc.'s subsidiaries relating to the treatment of oral mucositis and the other with ILH Holdings, Inc., relating to the development of novel antibiotics.

    For more information about Oragenics, please visit www.oragenics.com.

    Safe Harbor Statement

    Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements and information that reflect management's current views with respect to the Company's expectations, plans, business outlook, future events and performance, including, but not limited to, those regarding the potential benefits of, and plans relating to, the Company's acquisition of Noachis Terra and the Company's ability to develop and commercialize the TerraCoV2 vaccine. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

    View Full Article Hide Full Article
  5. Oragenics, Inc. (NYSE:OGEN), (the "Company" or "Oragenics"), today announced its acquisition of Noachis Terra Inc., following its entry into a stock purchase agreement (the "Stock Purchase Agreement"), to develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus ("SARS-CoV-2"), the root cause of coronavirus disease 2019 ("COVID-19"). Noachis Terra Inc., holds a worldwide, nonexclusive license to the TerraCoV2 vaccine candidate from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institute of Health ("NIH"). The Company's acquisition of Noachis Terra and its TerraCoV2 immunization product candidate represents its first step towards…

    Oragenics, Inc. (NYSE:OGEN), (the "Company" or "Oragenics"), today announced its acquisition of Noachis Terra Inc., following its entry into a stock purchase agreement (the "Stock Purchase Agreement"), to develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus ("SARS-CoV-2"), the root cause of coronavirus disease 2019 ("COVID-19"). Noachis Terra Inc., holds a worldwide, nonexclusive license to the TerraCoV2 vaccine candidate from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institute of Health ("NIH"). The Company's acquisition of Noachis Terra and its TerraCoV2 immunization product candidate represents its first step towards accessing pioneering technologies to reduce the global threat posed by COVID-19, which aligns with the company's existing anti-infective programs.

    "Our strategic acquisition of Noachis Terra marks a significant milestone in our history, as we are now prepared to advance the development of immunizations that target the devastating COVID-19 pandemic," stated Alan Joslyn, Ph.D., president and CEO of Oragenics. "We have long sought innovative medical solutions to society's problems, and we believe that acquiring Noachis Terra at the beginning of its TerraCoV2 development is an exceptional opportunity for us to bolster our existing pipeline of product candidates in infectious disease. What makes us so excited about collaborating with Noachis Terra going forward is the involvement of Noachis Terra's Consulting Director of Research and Development, David Zarley, Ph.D., who brings a wealth of knowledge in vaccine research and development, having been involved in the creation of Flumist®, parainfluenza and rotavirus vaccine candidates during his career. We are hopeful that our combined efforts can provide a breakthrough response to COVID-19 and drive life-changing protection for the individuals most at risk to this pandemic.

    "With this acquisition completed, we can now begin to capitalize on the prefusion coronavirus spike protein research, as well as its potential applications, that are covered by Noachis Terra's license with the NIH by advancing TerraCoV2 toward the clinical research and trial stages. I believe Dr. Zarley's management of Noachis Terra's TerraCoV2 development program will enable us to leverage our existing industry expertise and scientific capabilities and refocus our efforts on the creation of a potentially life-altering solution to COVID-19."

    Although the research and potential applications covered by Noachis Terra's NIH license are substantial, the Food and Drug Administration has not yet approved a vaccine for the prevention of SARS-CoV-2 or COVID-19. Relying on the intellectual property obtained through the NIH license, the Company will look to accelerate activities to enter clinical trials in late 2020 or early 2021 Prior to the acquisition, Noachis Terra has filed funding applications with both the NIH/NIAID and the Biomedical Advanced Research and Development Authority ("BARDA"), which has previously provided funding to companies developing vaccine candidates for coronaviruses. At this time, the Company plans to finance the clinical trials for TerraCoV2 with its available cash and any grant funds that may be awarded by BARDA or NIH. Dr. Joslyn added, "Noachis Terra has identified adjuvant candidates for TerraCoV2 production, as well as experienced clinical research and development organizations that are prepared to support the Company's goal of accelerating the pace of clinical development for TerraCov2."

    Joseph Hernandez, the founder and former sole shareholder of Noachis Terra, said, "I've always believed that two heads are better than one, and Oragenics' strategic acquisition of Noachis Terra creates a powerful network of immunization experts and professionals who carry substantial knowledge in the initial development and production, regulatory approval, and commercialization and marketing of vaccines. I believe Oragenics can use this enriched network to establish itself as a unique player in the field of SARS-CoV-2 immunization development. With Oragenics' critical support, our team is prepared to fast-track the development of TerraCov2 and to begin the clinical stage research that will be crucial to the development and future production of a SARS-CoV-2 vaccine, the culmination of which could set the stage for Oragenics to be a leader in the global effort to shut down the disease's transmission in the future."

    As a result of the acquisition, the Company (i) paid an aggregate of $1,925,000 in cash, a portion of which was applied to retire outstanding obligations of Noachis Terra with the balance being paid to Mr. Hernandez, (ii) issued 9,200,000 shares of common stock of the Company and warrants to purchase 9,200,000 shares of common stock of the Company, carrying an exercise price of $1.25 per share and a five-year term, and (iii) may be obligated to pay Mr. Hernandez certain contingent cash consideration in the future in accordance with the Stock Purchase Agreement, in exchange for 100% of the issued and outstanding common stock of Noachis Terra, which became a wholly-owned subsidiary of the Company. Pursuant to the Stock Purchase Agreement, the Company is committed to filing a registration statement covering the newly-issued shares of common stock, while the exercise of the warrants to purchase shares of the Company's common stock are subject to shareholder approval, which the Company intends to solicit in connection with its 2020 annual meeting of the shareholders.

    About Coronaviruses

    According to the National Institute of Allergy and Infectious Diseases, coronaviruses are a large family of viruses that cause upper-respiratory tract infections. In recent decades, multiple coronaviruses have moved from animal carriers to human carriers, including the novel coronavirus, SARS-CoV-2, which causes the coronavirus disease, COVID-19.

    About Oragenics, Inc.

    Oragenics, Inc. is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for oral mucositis and novel antibiotics against infectious disease. Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from the novel coronavirus, SARS-CoV-2, which causes the coronavirus disease 2019, COVID-19. The TerraCoV2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health, which is under a worldwide, nonexclusive intellectual property license to Noachis Terra. In addition, Oragenics also has two exclusive worldwide channel collaborations, one with Precigen, Inc.'s subsidiaries relating to the treatment of oral mucositis and the other with ILH Holdings, Inc., relating to the development of novel antibiotics.

    For more information about Oragenics, please visit www.oragenics.com.

    Safe Harbor Statement

    Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements and information that reflect management's current views with respect to the Company's expectations, plans, business outlook, future events and performance, including, but not limited to, those regarding the potential benefits of, and plans relating to, the Company's acquisition of Noachis Terra and the Company's ability to develop and commercialize the TerraCoV2 vaccine. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Although the Company's management believes the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to numerous factors, risks and uncertainties, many of which are difficult to predict, are generally beyond the control of the Company and which may cause actual events or results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These factors, risks and uncertainties include, among others, both known and unknown, the following: The Company's ability to advance the development of TerraCoV2 under the timelines and in accord with the milestones it projects; the Company's ability to obtain funding for the development of Noachis Terra's TerraCoV2 vaccine, whether through its own cash on hand, a grant from BARDA, or another alternative source; the regulatory application process, research and development stages, and future clinical data and analysis relating to TerraCoV2, including any decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable; the Company's ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments; other potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, interruptions to manufacturers and supply chains, adverse impacts on healthcare systems and disruption of the global economy; and general economic and market conditions and other important risk factors set forth under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and other filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

    View Full Article Hide Full Article
View All Oragenics Inc. News